Similarly, in HER2+ breast cancer, IGF-1R cooperates with HER2/ERBB2 signaling to sustain downstream PI3K/AKT and MAPK activation, thereby undermining the efficacy of HER2-targeted agents such as trastuzumab [60]. This evidence concerns the gene IGF1R and breast carcinoma.